Filing Flows › Bausch Health Companies (BHC) › R&D spending
Bausch Health Companies (BHC) R&D spending by quarter
Bausch Health Companies' R&D spending was $141M in Q3 2026 (third quarter 2026), -18% from Q2 2026. Over the last 7 quarters it ranged from $141M (Q3 2026) to $173M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $141M | -18% | -15% |
| Q2 2026 | $173M | +6% | +9% |
| Q1 2026 | $163M | +1% | +14% |
| Q4 2025 | $161M | -3% | — |
| Q3 2025 | $166M | +4% | — |
| Q2 2025 | $159M | +11% | — |
| Q1 2025 | $143M | — | — |
Q3 2026 at a glance
Bausch Health Companies, Q3 2026: revenue $2.9B (+10% year over year), operating margin 33.4%, net earnings $436M, operating cash flow $814M. The chart follows the revenue to costs, profit and cash.
Questions
What is Bausch Health Companies' R&D spending?
Bausch Health Companies' R&D spending was $141M in Q3 2026 (third quarter 2026), -18% from Q2 2026.
How has Bausch Health Companies' R&D spending changed?
Over the last 7 quarters it ranged from $141M (Q3 2026) to $173M (Q2 2026).
Q3 2026 results → · How Bausch Health Companies makes money →